Phone: 1-647-923-2770
Margaret Hux, MSc.

Health Economics and Health Technology
Research Consulting

 
Marg@MargaretHux.ca
 

Supporting Market Access for Medications and other Health Technologies

Selected Presentations:

  • Yoshida EM, Mason A, Peltekian K, Lilly L, Marotta P, Wong M, Hux M, Fischer SL, Thiele SL, Borelli R.
    The current state of liver transplantation in Canada EASL.
    The International Liver Congress 2017.
     
  • Hux M, Zou D, Ma E, Sajosi P, Engstrom A, Selby R, Benson E, Teasell J, Richhariya A, Briggs A, Bonthapally V.
    Cost-effectiveness of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma.
    Poster presented at the 2016 American Society of Clinical Oncology Quality Care Symposium (ASCO-QC), in Phoenix, AZ, USA, February 26–27, 2016.
     
  • M Hux, C Li, N Risebrough, R Goeree, M Sculpher, A Kapur, A Briggs.
    Coverage with Evidence Development: Opportunities for improving access to new technologies in the Canadian environment.
    Poster presentation at CAPT Conference November 2014. Toronto ON.
     
  • C Li, N Risebrough, M Hux.
    Coverage with Evidence Development activities around the world: An environment scan. Poster
    PHP267 presented at ISPOR Europe Conference November 2014. Amsterdam, the Netherlands.
     
  • M Hux, D Lawrence, F Aissa, R Aultman, E Carr, D Steward.
    Economic Evaluation of Rituximab in the First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) in Canada.
    CADTH Symposium, April 18, 2010, Halifax, NS.
     
  • M Malmenäs, M Hux, M Novotny, L Abrahamyan.
    Analysis of Effectiveness and Cost-Effectiveness in Patient Registries.
    ISPOR Congress May 19, 2009, Orlando, Florida.
     
  • D Marshall, M Hux.
    Health Care Costs: Standardized Methods and Estimates for Research and Policy Applications. Design and Analysis Issues for Economic Analysis Alongside Clinical Trials.
    Presentation at AHRQ Conference. 2008.
     
  • M. Gagnon, B. Rive, M. Hux, J. Cochran, C Guilhaume.
    Rational choice of treatment strategy in moderate to severe Alzheimer’s disease patients living in Canada.
    ISPOR 9th Annual European Congress - October 28-31, 2006 Copenhagen Denmark
     
  • A. Manca, M. Hux, S. Aballea, S. Quilici, M. Drummond.
    Exploring the variability in cost-effectiveness results within multi-country clinical trials.
    Cochrane Colloquium. Melbourne, Australia 2005.
     
  • M. Drummond, J. Chancellor, M. Hux, D. Becker, I. Duprat-Lomon, P.-P. Sagnier.
    Economic Evaluation demonstrates that moxifloxacin IV/PO monotherapy is cost-effective to the U.K. National Health Service when compared to IV/PO amoxicillin/ clavanulate ± clarithromycin in the treatment of community-acquired pneumonia.
    European Congress of Clinical Microbiology and Infectious Diseases. Glasgow, Scotland. May 2003.
     
  • M. Drummond, J. Chancellor, I. Duprat-Lomon, P.-P. Sagnier, M Barbieri, D. Becker, M. Hux.
    Economic evaluation demonstrates that moxifloxacin IV/PO monotherapy is cost-effective to the Spanish National Health System when compared to IV/PO amoxicillin/clavulanate ± clarithromycin in the treatment of community-acquired pneumonia.
    International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Rotterdam, Holland.  Nov. 2002.
     
  • M. Drummond, D. Becker, M. Hux, J. Chancellor, I. Duprat-Lomon, P.-P. Sagnier.
    Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ± clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare systems.
    European Respiratory Society (ERS), Stockholm, Sweden. 17th September 2002.
     
  • Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Emir B, Subbiah P, Mastey V.
    Improved health outcomes with donepezil in moderate to severe Alzheimer’s disease are associated with economic benefits. Poster.
    The 8th International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden, July 21-25, 2002.
     
  • J. Chancellor, M. Drummond, I. Duprat-Lomon, P.-P. Sagnier, F. Baldamus, D. Becker, M. Hux. Economic evaluation demonstrates that moxifloxacin IV/PO monotherapy is cost-effective to the German health care system when compared to IV/PO amoxicillin/ clavulanate ± clarithromycin in the treatment of community-acquired pneumonia. Poster Presentation.
    18th Annual Meeting of the International Society of Technology Assessment in Health Care (ISTAHC). 09 June, 2002 — 12 June, 2002 Berlin, Germany
     
  • M. Drummond, D. Becker, M. Hux, J. Chancellor, I. Duprat-Lomon, P-P. Sagnier.
    Economic Evaluation of Moxifloxacin in the Treatment of Community-Acquired Pneumonia. Oral Presentation by Dr. Drummond, International Society for Pharmacoeconomics and Outcomes Research
    (ISPOR), Arlington, VA, USA. May 19-22, 2002.
     
  • Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Emir B, Subbiah P, Mastey V.
    Differences in Alzheimer's disease resource utilization across countries does not preclude pooling data in a multinational trial.
    Presented orally by Dr Feldman at the European Neurological Society Meeting. Berlin, April 22-26, 2002.
     
  • M. Drummond, D. Becker, M. Hux, J. Chancellor, I. Duprat-Lomon, P-P. Sagnier.
    Can moxifloxacin IV/PO improve health outcomes and reduce hospital costs?
    12th Annual European Congress of Clinical Microbiology and Infections Diseases (ECCMID). Press Conference by J Chancellor, 25th April 2002.
     
  • Drummond M, Finch R, Duprat-Lomon I, Sagnier P-P, Collins O, Kubin R, Hux M.
    Superior outcomes with moxifloxacin (MXF) IV/PO monotherapy compared to IV/PO amoxicillin/clavulanate (AMC) ± clarithromycin (CLA) in the treatment of community-acquired pneumonia (CAP).
    Poster presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December 2001.
     
  • Hux, M., Milkovich, N., Torrance, G, Sibbald G.
    Health Related Quality of Life related to Chronic Foot Ulcers in Diabetics.
    Presented at the International Society for Quality of Life Research. Barcelona. November, 1999.
     
  • Sibbald, G., Hux, M., Milkovich, N., Attard, C., Torrance, G.
    Cost-effectiveness analysis of becaplermin for non-healing neuropathic diabetic foot ulcers.
    Presented at the Second Western Canadian Association of Wound Care and Sixth Biennial Foot & Lower Extremity Conferences. Calgary Alberta, April 1999.
    Awarded Best Poster.
     
  • Haider S, Benhaddad A, Rosner AJ, Ryan N, Hux M.
    Quality of Life and pharmacoeconomic aspects of hormone replacement therapy in post-menopausal women – A Canadian randomized trial.
    International Society for Pharmcoeconomics and Outcomes Research. May 1998.
     
  • Hux M.J., O’Brien B.J., Iskedjian M., Goeree R., Gagnon M., Gauthier S.
    Relationship between Severity of Alzheimer’s Disease and Costs of Caring.
    Dementia ‘97: Exploring Our Options, Conference, Vancouver, October 1997